

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 29, 2010 (November 29, 2010)

---

**Protalix BioTherapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

Florida  
(State or other jurisdiction  
of incorporation)

001-33357  
(Commission File Number)

65-0643773  
(IRS Employer  
Identification No.)

2 Sunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices)

20100  
(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events**

On November 29, 2010, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits****(d) Exhibits**

99.1 Press release dated November 29, 2010.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: November 29, 2010

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer

**Pfizer and Protalix BioTherapeutics Announce Submission of  
taliglucerase alfa for European Marketing Authorization  
for the Treatment of Gaucher Disease**

**New York, NY/Carmiel, Israel, November 29, 2010** — Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment of Gaucher disease on March 23, 2010.

On November 30, 2009, Pfizer and Protalix BioTherapeutics, Inc. entered into an agreement to develop and commercialize taliglucerase alfa. Under the terms of the agreement, Pfizer received exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix retained the exclusive commercialization rights in Israel.

Taliglucerase alfa was granted orphan drug designation by the U.S. Food and Drug Administration. A New Drug Application (NDA) for taliglucerase alfa has been accepted by the FDA and assigned a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011. Taliglucerase alfa is available to patients with Gaucher disease in the United States under an Expanded Access protocol as well as to patients in several member states of the European Union, Israel and other countries under Named Patient provisions.

---

DISCLOSURE NOTICE: The information contained in this release is as of November 29, 2010. Neither Pfizer nor Protalix BioTherapeutics assumes any obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Drug discovery and development involve a high degree of risk. Factors that might cause material differences include, among others, risks relating to: the review process of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), other foreign regulatory bodies and other governmental regulatory bodies, including the risk that regulatory authorities may find that the data from Protalix BioTherapeutics' clinical trials and other studies is insufficient for regulatory approval; delays in the FDA's, the EMA's or other health regulatory authorities' approval of any applications Protalix BioTherapeutics and/or Pfizer file or refusals to approve such filings, including the New Drug Application (NDA) filed with the FDA and the Marketing Authorization Application (MAA) submitted to the EMA for taliglucerase alfa for the treatment of Gaucher disease; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application filed for any such drug product; risks relating to the decisions of the FDA, EMA and other foreign regulatory authorities regarding labeling and other matters that could affect the commercial availability or potential of taliglucerase alfa; risks relating to competitive developments regarding taliglucerase alfa; and other factors described in Pfizer's and Protalix BioTherapeutics' filings with the Securities and Exchange Commission. Even if favorable testing data is generated from clinical trials of drug products, the FDA, EMA or any other foreign regulatory authority may not accept or approve an NDA or MAA, as applicable, filed by a pharmaceutical or biotechnology company for such drug product.

---

**Pfizer Contacts:**

Joan Campion (Media)

212 733-2798

[Joan.Campion@Pfizer.com](mailto:Joan.Campion@Pfizer.com)

Suzanne Harnett (Investors)

212 733-8009

[Suzanne.Harnett@Pfizer.com](mailto:Suzanne.Harnett@Pfizer.com)

In Europe:

Lisa O'Neill

44 1737-331536

[Lisa.O'Neill@pfizer.com](mailto:Lisa.O'Neill@pfizer.com)

**Protalix Contacts:**

Marcy Nanus (Investors)

The Trout Group, LLC

646 378-2927

[Mnanus@troutgroup.com](mailto:Mnanus@troutgroup.com)

Kari Watson (Media)

MacDougall Biomedical

Communications

781-235-3060

[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)

#####